Another tumor-specific antigen, Interleukin 13 receptor α2 (IL13Rα2), linked to GBM poor prognosis, has been used to engineer IL13Ra2-specific CAR-T cells to be infused via a catheter/reservoir system into the resection cavity in a pilot safety and feasibility trial that demonstrated fair tolerability and transient anti-glioma responses in 2 out of 3 patients treated [116]. This evidence concerns the gene IL13RA2 and central nervous system cancer.